Search - tctmd.com

Displaying 121 - 140 of 346

Sort: Relevancy | Date

Presentation TCT 2019

Infarct Size Reduction: From the First FDA-Approved Therapy (SSO2) to Novel Approaches

Presenter: Gregg Stone

September 26, 2019

Presentation TCT 2019

No Reflow: How to Prevent It and How to Fix It!

Presenter: Mitul Patel

September 26, 2019

Presentation TCT 2019

Case 1: A Patient With STEMI and Multivessel Disease

Presenter: Colin Berry

September 26, 2019

Presentation TCT 2019

A Woman’s Perspective!: Minoca, SCAD, Takotsubo, etc.

Presenter: Jacqueline Saw

September 26, 2019

Presentation TCT 2019

STEMI 2019: Who Are the High-Risk Patients?

Presenter: Andreas Baumbach

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

Presentation TCT 2019

When IVUS-OCT Guidance is a Need: Highly Calcified Lesions and ACS

Presenter: Francesco Prati

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Role of PCSK9 Inhibitors Post-PCI and ACS

Presenter: Marc Bonaca

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

SSO2 Therapy: Case Study

Presenter: Richard Schatz

September 26, 2019

Presentation TCT 2019

SSO2 Therapy: Clinical Evidence and Outcomes

Presenter: Gregg Stone

September 26, 2019

Presentation TCT 2019

SuperSaturated Oxygen Therapy: Background and Mechanism of Action

Presenter: James Spears

September 26, 2019

Presentation TCT 2019

Failed Therapeutic Approaches (Drugs and Devices) to Reduce Infarct Size

Presenter: E. Magnus Ohman

September 26, 2019

Presentation TCT 2019

Importance of Infarct Size and Microvascular Obstruction in STEMI

Presenter: Suzanne de Waha

September 26, 2019

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

Todd Neale

September 25, 2019

Advertisement

Infarct Size Reduction: From the First FDA-Approved Therapy (SSO2) to Novel Approaches

No Reflow: How to Prevent It and How to Fix It!

Case 1: A Patient With STEMI and Multivessel Disease

A Woman’s Perspective!: Minoca, SCAD, Takotsubo, etc.

STEMI 2019: Who Are the High-Risk Patients?

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

When IVUS-OCT Guidance is a Need: Highly Calcified Lesions and ACS

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Role of PCSK9 Inhibitors Post-PCI and ACS

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

SSO2 Therapy: Case Study

SSO2 Therapy: Clinical Evidence and Outcomes

SuperSaturated Oxygen Therapy: Background and Mechanism of Action

Failed Therapeutic Approaches (Drugs and Devices) to Reduce Infarct Size

Importance of Infarct Size and Microvascular Obstruction in STEMI

Strokes Increasing in STEMI Patients With Cardiogenic Shock

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content